Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Argininosuccinate lyase deficiency causes blood-brain barrier disruption via nitric oxide–mediated dysregulation of claudin expression
Jordan Kho, Urszula Polak, Ming-Ming Jiang, John D. Odom, Jill V. Hunter, Saima M. Ali, Lindsay C. Burrage, Sandesh C.S. Nagamani, Robia G. Pautler, Hannah P. Thompson, Akihiko Urayama, Zixue Jin, Brendan Lee
Jordan Kho, Urszula Polak, Ming-Ming Jiang, John D. Odom, Jill V. Hunter, Saima M. Ali, Lindsay C. Burrage, Sandesh C.S. Nagamani, Robia G. Pautler, Hannah P. Thompson, Akihiko Urayama, Zixue Jin, Brendan Lee
View: Text | PDF
Research Article Genetics Neuroscience

Argininosuccinate lyase deficiency causes blood-brain barrier disruption via nitric oxide–mediated dysregulation of claudin expression

  • Text
  • PDF
Abstract

Nitric oxide (NO) is a critical signaling molecule that has been implicated in the pathogenesis of neurocognitive diseases. Both excessive and insufficient NO production have been linked to pathology. Previously, we have shown that argininosuccinate lyase deficiency (ASLD) is a novel model system to investigate cell-autonomous, nitric oxide synthase–dependent NO deficiency. Humans with ASLD are at increased risk for developing hyperammonemia due to a block in ureagenesis. However, natural history studies have shown that individuals with ASLD have multisystem disease including neurocognitive deficits that can be independent of ammonia. Here, using ASLD as a model of NO deficiency, we investigated the effects of NO on brain endothelial cells in vitro and the blood-brain barrier (BBB) in vivo. Knockdown of ASL in human brain microvascular endothelial cells (HBMECs) led to decreased transendothelial electrical resistance, indicative of increased cell permeability. Mechanistically, treatment with an NO donor or inhibition of Claudin-1 improved barrier integrity in ASL-deficient HBMECs. Furthermore, in vivo assessment of a hypomorphic mouse model of ASLD showed increased BBB leakage, which was partially rescued by NO supplementation. Our results suggest that ASL-mediated NO synthesis is required for proper maintenance of brain microvascular endothelial cell functions as well as BBB integrity.

Authors

Jordan Kho, Urszula Polak, Ming-Ming Jiang, John D. Odom, Jill V. Hunter, Saima M. Ali, Lindsay C. Burrage, Sandesh C.S. Nagamani, Robia G. Pautler, Hannah P. Thompson, Akihiko Urayama, Zixue Jin, Brendan Lee

×

Figure 4

BBB breakdown in AslNeo/Neo mice as shown by Evans blue fluorescent tracer extravasation.

Options: View larger image (or click on image) Download as PowerPoint
BBB breakdown in AslNeo/Neo mice as shown by Evans blue fluorescent trac...
(A) Representative picture of gross distribution of Evans blue–conjugated albumin after I.V. injection in WT, mutant (AslNeo/Neo), and sodium nitrite–treated mutant mice (AslNeo/Neo + NO). (B) Two-photon images of cerebral vasculature shown as (i) maximal intensity plots and (ii) fluorescence intensity maps. Box (50 × 50 μm) plots and line (70 μm) profile of fluorescence intensity were measured at the designated locations. The box color corresponds to the genotype legend in B, D, and E. (C) Box plot ROI intensity (WT: 42.3 ± 1.9 A.U./μm2. AslNeo/Neo: 125.4 ± 3.4 A.U./μm2. AslNeo/Neo + NO: 104.1 ± 1.9 A.U./μm2.) WT: n = 4 mice, 3–6 images per mouse, 6–8 ROIs per image. Total 123 ROI determinations. AslNeo/Neo: n = 4 mice, 3–5 images per mouse, 6–8 ROIs per image. Total 116 ROI determinations. AslNeo/Neo + NO: n = 5 mice, 3–5 images per mouse, 6–8 ROIs per image. Total 134 ROI determinations. Mean ± SE. (D) Line profile of fluorescence intensity. Extravascular fluorescence levels were estimated by the area under the curves of the pixel intensity by subtracting that of blood vessel. (E) The extravascular AUC. (WT: 36,179 ± 3,836 A.U. AslNeo/Neo: 86,453 ± 10,419 A.U. AslNeo/Neo + NO: 55,036 ± 3,377 A.U.) Line profiles were presented as the pixel intensity. WT: n = 4 mice, 4-line profiles per image, 16 image determinations. AslNeo/Neo: n = 4 mice, 4-line profiles per image, 21 image determinations. AslNeo/Neo + NO: n = 5 mice, 4-line profiles per image, 14 image determinations. Bar graphs represent mean values while error bars represent the SE. *P < 0.05, ***P < 0.001, and ****P < 0.0001. One-way ANOVA followed by Newman-Keuls test. I.V., intravenous.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts